vs
Side-by-side financial comparison of ENCORE CAPITAL GROUP INC (ECPG) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $473.6M, roughly 1.3× ENCORE CAPITAL GROUP INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 16.2%, a 18.3% gap on every dollar of revenue. On growth, ENCORE CAPITAL GROUP INC posted the faster year-over-year revenue change (78.3% vs 4.8%). Over the past eight quarters, ENCORE CAPITAL GROUP INC's revenue compounded faster (20.1% CAGR vs 4.6%).
Encore Capital Group, Inc. is a publicly traded debt buyer based in the United States. The company is headquartered in San Diego, and operates throughout the United States. The firm is a publicly traded NASDAQ Global Select company (ECPG), a component stock of the Russell 2000, the S&P SmallCap 600, and the Wilshire 4500.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ECPG vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $473.6M | $622.0M |
| Net Profit | $76.7M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | 62.4% |
| Net Margin | 16.2% | 34.4% |
| Revenue YoY | 78.3% | 4.8% |
| Net Profit YoY | — | 2.9% |
| EPS (diluted) | $3.32 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $473.6M | $622.0M | ||
| Q3 25 | $460.4M | $609.3M | ||
| Q2 25 | $442.1M | $578.7M | ||
| Q1 25 | $392.8M | $568.2M | ||
| Q4 24 | $265.6M | $593.6M | ||
| Q3 24 | $367.1M | $564.7M | ||
| Q2 24 | $355.3M | $537.3M | ||
| Q1 24 | $328.4M | $568.0M |
| Q4 25 | $76.7M | $214.2M | ||
| Q3 25 | $74.7M | $288.2M | ||
| Q2 25 | $58.7M | $30.2M | ||
| Q1 25 | $46.8M | $238.3M | ||
| Q4 24 | — | $208.2M | ||
| Q3 24 | $30.6M | $544.0M | ||
| Q2 24 | $32.2M | $102.0M | ||
| Q1 24 | $23.2M | $4.8M |
| Q4 25 | 36.6% | 62.4% | ||
| Q3 25 | 37.6% | 70.1% | ||
| Q2 25 | 34.1% | 36.3% | ||
| Q1 25 | 32.9% | 94.0% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | 28.9% | — | ||
| Q2 24 | 28.7% | 50.2% | ||
| Q1 24 | 25.5% | -13.0% |
| Q4 25 | 16.2% | 34.4% | ||
| Q3 25 | 16.2% | 47.3% | ||
| Q2 25 | 13.3% | 5.2% | ||
| Q1 25 | 11.9% | 41.9% | ||
| Q4 24 | — | 35.1% | ||
| Q3 24 | 8.3% | 96.3% | ||
| Q2 24 | 9.1% | 19.0% | ||
| Q1 24 | 7.1% | 0.8% |
| Q4 25 | $3.32 | $0.49 | ||
| Q3 25 | $3.17 | $0.67 | ||
| Q2 25 | $2.49 | $0.07 | ||
| Q1 25 | $1.93 | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | $1.26 | $1.21 | ||
| Q2 24 | $1.34 | $0.23 | ||
| Q1 24 | $0.95 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $156.8M | $618.7M |
| Total DebtLower is stronger | $4.0B | $9.0B |
| Stockholders' EquityBook value | $976.8M | $9.7B |
| Total Assets | $5.3B | $19.6B |
| Debt / EquityLower = less leverage | 4.13× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $156.8M | $618.7M | ||
| Q3 25 | $172.5M | $938.9M | ||
| Q2 25 | $172.9M | $631.9M | ||
| Q1 25 | $187.1M | $1.1B | ||
| Q4 24 | $199.9M | $929.0M | ||
| Q3 24 | $247.4M | $950.1M | ||
| Q2 24 | $250.6M | $1.8B | ||
| Q1 24 | $173.0M | $843.0M |
| Q4 25 | $4.0B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $3.7B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $976.8M | $9.7B | ||
| Q3 25 | $952.9M | $9.6B | ||
| Q2 25 | $896.0M | $9.5B | ||
| Q1 25 | $819.1M | $9.8B | ||
| Q4 24 | $767.3M | $10.3B | ||
| Q3 24 | $1.0B | $10.3B | ||
| Q2 24 | $988.1M | $9.8B | ||
| Q1 24 | $953.9M | $9.9B |
| Q4 25 | $5.3B | $19.6B | ||
| Q3 25 | $5.3B | $19.3B | ||
| Q2 25 | $5.2B | $18.3B | ||
| Q1 25 | $5.0B | $17.6B | ||
| Q4 24 | $4.8B | $18.2B | ||
| Q3 24 | $5.0B | $18.0B | ||
| Q2 24 | $4.8B | $17.7B | ||
| Q1 24 | $4.7B | $16.1B |
| Q4 25 | 4.13× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 4.83× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $153.2M | $827.1M |
| Free Cash FlowOCF − Capex | $126.9M | — |
| FCF MarginFCF / Revenue | 26.8% | — |
| Capex IntensityCapex / Revenue | 5.5% | — |
| Cash ConversionOCF / Net Profit | 2.00× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $244.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $153.2M | $827.1M | ||
| Q3 25 | $81.6M | $702.6M | ||
| Q2 25 | $9.5M | $364.0M | ||
| Q1 25 | $45.3M | $596.1M | ||
| Q4 24 | $156.2M | $742.5M | ||
| Q3 24 | $45.9M | $703.6M | ||
| Q2 24 | $35.7M | $658.2M | ||
| Q1 24 | $51.0M | $664.6M |
| Q4 25 | $126.9M | — | ||
| Q3 25 | $75.6M | — | ||
| Q2 25 | $3.2M | — | ||
| Q1 25 | $38.3M | — | ||
| Q4 24 | $127.2M | — | ||
| Q3 24 | $39.7M | — | ||
| Q2 24 | $28.3M | — | ||
| Q1 24 | $44.1M | — |
| Q4 25 | 26.8% | — | ||
| Q3 25 | 16.4% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 9.7% | — | ||
| Q4 24 | 47.9% | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | 13.4% | — |
| Q4 25 | 5.5% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | 2.00× | 3.86× | ||
| Q3 25 | 1.09× | 2.44× | ||
| Q2 25 | 0.16× | 12.06× | ||
| Q1 25 | 0.97× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 1.50× | 1.29× | ||
| Q2 24 | 1.11× | 6.45× | ||
| Q1 24 | 2.19× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECPG
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
